[go: up one dir, main page]

HRP20090679T1 - Upotreba oksikodona za liječenje organske boli - Google Patents

Upotreba oksikodona za liječenje organske boli Download PDF

Info

Publication number
HRP20090679T1
HRP20090679T1 HR20090679T HRP20090679T HRP20090679T1 HR P20090679 T1 HRP20090679 T1 HR P20090679T1 HR 20090679 T HR20090679 T HR 20090679T HR P20090679 T HRP20090679 T HR P20090679T HR P20090679 T1 HRP20090679 T1 HR P20090679T1
Authority
HR
Croatia
Prior art keywords
pain
oxycodone
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
HR20090679T
Other languages
English (en)
Croatian (hr)
Inventor
Mohr Drewes Asbjorn
Arendt Nielsen Lars
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090679(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of HRP20090679T1 publication Critical patent/HRP20090679T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HR20090679T 2005-01-18 2006-01-17 Upotreba oksikodona za liječenje organske boli HRP20090679T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
HRP20090679T1 true HRP20090679T1 (hr) 2010-01-31

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090679T HRP20090679T1 (hr) 2005-01-18 2006-01-17 Upotreba oksikodona za liječenje organske boli

Country Status (31)

Country Link
US (2) US20080200493A1 (uk)
EP (1) EP1838318B1 (uk)
JP (1) JP5049139B2 (uk)
KR (10) KR20230170811A (uk)
CN (1) CN101106996B (uk)
AP (1) AP2249A (uk)
AR (1) AR052880A1 (uk)
AT (2) ATE446092T1 (uk)
AU (1) AU2006207498B2 (uk)
BR (1) BRPI0606247A2 (uk)
CA (1) CA2595043C (uk)
CY (1) CY1109660T1 (uk)
DE (2) DE202006019887U1 (uk)
DK (2) DK1838318T3 (uk)
EA (1) EA013544B1 (uk)
ES (1) ES2333901T3 (uk)
HR (1) HRP20090679T1 (uk)
IL (1) IL184530A (uk)
ME (1) ME01066B (uk)
MX (1) MX2007007207A (uk)
MY (1) MY144471A (uk)
NO (1) NO338968B1 (uk)
NZ (1) NZ555852A (uk)
PL (1) PL1838318T3 (uk)
PT (1) PT1838318E (uk)
RS (1) RS51069B (uk)
SI (1) SI1838318T1 (uk)
TW (1) TWI432196B (uk)
UA (1) UA85471C2 (uk)
WO (1) WO2006077212A1 (uk)
ZA (1) ZA200705231B (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957106B2 (en) 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
NZ555852A (en) 2010-01-29
ES2333901T3 (es) 2010-03-02
AU2006207498B2 (en) 2009-11-19
UA85471C2 (uk) 2009-01-26
KR20210131450A (ko) 2021-11-02
NO20074174L (no) 2007-10-17
CA2595043A1 (en) 2006-07-27
US9271974B2 (en) 2016-03-01
DE602006009899D1 (de) 2009-12-03
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
AR052880A1 (es) 2007-04-11
KR20120089710A (ko) 2012-08-13
KR20140091782A (ko) 2014-07-22
PL1838318T3 (pl) 2010-03-31
SI1838318T1 (sl) 2010-02-26
KR20200128451A (ko) 2020-11-12
PT1838318E (pt) 2009-12-15
DK200700207U3 (da) 2007-09-28
JP2008526927A (ja) 2008-07-24
RS51069B (sr) 2010-10-31
ME01066B (me) 2012-10-20
HK1107933A1 (en) 2008-04-25
MY144471A (en) 2011-09-30
KR20220165797A (ko) 2022-12-15
CN101106996B (zh) 2013-10-23
KR20080106991A (ko) 2008-12-09
BRPI0606247A2 (pt) 2009-06-09
NO338968B1 (no) 2016-11-07
ZA200705231B (en) 2008-06-25
EP1838318A1 (en) 2007-10-03
US20150190393A1 (en) 2015-07-09
AP2007004057A0 (en) 2007-08-31
WO2006077212A1 (en) 2006-07-27
DK200700207U1 (da) 2007-08-24
IL184530A (en) 2015-01-29
CY1109660T1 (el) 2014-08-13
CN101106996A (zh) 2008-01-16
CA2595043C (en) 2013-11-19
KR20190135557A (ko) 2019-12-06
IL184530A0 (en) 2007-10-31
ATE446092T1 (de) 2009-11-15
DE202006019887U1 (de) 2007-07-26
AU2006207498A1 (en) 2006-07-27
US20080200493A1 (en) 2008-08-21
JP5049139B2 (ja) 2012-10-17
EA200701541A1 (ru) 2008-02-28
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
KR20070100368A (ko) 2007-10-10
EP1838318B1 (en) 2009-10-21
DK1838318T3 (da) 2010-01-04
EA013544B1 (ru) 2010-06-30
AP2249A (en) 2011-07-18
TW200637554A (en) 2006-11-01
KR20230170811A (ko) 2023-12-19

Similar Documents

Publication Publication Date Title
Kadriu et al. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments
HRP20090679T1 (hr) Upotreba oksikodona za liječenje organske boli
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
RU2011110765A (ru) Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
CA3037089C (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
KR101900520B1 (ko) 복합 조성물
JPH0222229A (ja) 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
JP2007302657A (ja) 痙症の兆候および症候の緩和方法
JP2018507243A5 (uk)
CN102204904A (zh) 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
JP2008526927A5 (uk)
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
NO20080244L (no) Doseringsstyring for prasugrel
JPWO2021202419A5 (uk)
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
RU2261098C2 (ru) Перорально распадающаяся композиция, содержащая миртазапин
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
CN100355450C (zh) 秦川通痹片
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis